MedTrace Logo

Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397

NCT01466244 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2017-05-17

No results posted yet for this study

Summary

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment.

PURPOSE: This research study is studying biomarkers in patients with metastatic or recurrent head and neck cancer treated with cisplatin and cetuximab on ECOG-E5397.

Conditions

Interventions

BIOLOGICAL

cetuximab

DRUG

cisplatin

GENETIC

gene expression analysis

GENETIC

microarray analysis

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Eastern Cooperative Oncology Group

    lead NETWORK

Principal Investigators

  • Barbara A. Burtness, MD · Fox Chase Cancer Center

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-11
Primary Completion
2012-01-11
Completion
2012-01-11

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01466244 on ClinicalTrials.gov